OIP — The Opportunity Intelligence PlatformOIP / Government Intelligence
Preparing the stored Government Intelligence discovery view.
OIP / Government Intelligence / Opportunity detail
Source: Stored live-derived Government dataNational Institutes of Health
OIP derived this review page from stored live-derived Government Intelligence source records. The official source and issuing agency remain authoritative.
Opportunity Intelligence Platform is an independent service and is not affiliated with or endorsed by the U.S. Government. Official notices, amendments, attachments, eligibility requirements, funding terms, and deadlines remain under source control.
OIP scores and explanations are informational and do not guarantee eligibility, suitability, compliance, contract award, or financial outcome.
No funding amount is disclosed in the stored source fields.
County governments; Native American tribal governments (Federally recognized); Public housing authorities/Indian housing authorities; Public and State controlled institutions of higher education; City or township governments; Special district governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; State governments; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education
2 warning(s) require review.
Objective score, derived by OIP
Publication decision: Publish with warning
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) -- a Grant (Grant) issued by National Institutes of Health.
Objective Government score 67 for grants-gov-357015, computed from source evidence and Government scoring configuration.
potential_value (not_applicable): potential_value is structurally not applicable for this Government category.
10 evidence record(s) support this pipeline result.
Next action: Review the official Grants.gov opportunity and follow the listed application package instructions.
95/100 · Ok
evidence_quality scored from source evidence and Government scoring guidance (value kind deterministic_calculation, confidence rank 0).
90/100 · Ok
confidence scored from source evidence and Government scoring guidance (value kind rule_based_evaluation, confidence rank 1).
No numeric value · Not Applicable
potential_value is structurally not applicable for this Government category.
62/100 · Ok
urgency scored from source evidence and Government scoring guidance (value kind deterministic_calculation, confidence rank 0).
56/100 · Ok
difficulty scored from source evidence and Government scoring guidance (value kind rule_based_evaluation, confidence rank 1).
62/100 · Ok
time_required scored from source evidence and Government scoring guidance (value kind rule_based_evaluation, confidence rank 1).
48/100 · Ok
capital_required scored from source evidence and Government scoring guidance (value kind rule_based_evaluation, confidence rank 1).
52/100 · Ok
risk scored from source evidence and Government scoring guidance (value kind rule_based_evaluation, confidence rank 1).
68/100 · Ok
novelty scored from source evidence and Government scoring guidance (value kind rule_based_evaluation, confidence rank 1).
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
$.detail.opportunityTitle · Field Mapping · 98/100 confidence
357015 / PAR-25-145
$.detail.id · Field Mapping · 99/100 confidence
National Institutes of Health
$.detail.synopsis.agencyName · Field Mapping · 97/100 confidence
Grant
$.detail.synopsis.fundingInstruments · Field Mapping · 96/100 confidence
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
$.detail.synopsis.synopsisDesc · Field Mapping · 94/100 confidence
2024-11-06T05:00:00.000Z
$.detail.synopsis.postingDate · Field Mapping · 96/100 confidence
2028-01-07T00:00:00.000Z
$.searchHit.closeDate · Field Mapping · 92/100 confidence
Applicant types: County governments; Native American tribal governments (Federally recognized); Public housing authorities/Indian housing authorities; Public and State controlled institutions of higher education; City or township governments; Special district governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; State governments; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education
Official source materials control eligibility, deadlines, amendments, attachments, and funding terms.
Open official source$.detail.synopsis.applicantTypes · Field Mapping · 94/100 confidence
value_not_disclosed
$.detail.synopsis · Field Mapping · 84/100 confidence
2024-11-06T18:21:43.000Z
$.detail.synopsis.lastUpdatedDate · Field Mapping · 88/100 confidence